TORNA ALL’ELENCO

Increased plasma levels of thrombopoietin in patients with severe acute pancreatitis in Critical Care

2013
AOU Città della Salute di Torino

Tipo pubblicazione

Conference Abstract

Autori/Collaboratori (9)Vedi tutti...

Pigozzi L

Bosco O

Vizio B


et alii...

Abstract

Introduction The aim of this study was to evaluate the accuracy of thrombopoietin (TPO) plasma levels as a biomarker of clinical severity in patients with acute pancreatitis (AP). TPO is a humoral growth factor that stimulates megakaryocyte proliferation and differentiation [1]. Furthermore, it favors platelet aggregation and polymorphonuclear leukocyte activation [2]. Elevated plasmatic concentrations of TPO have been shown in patients with critical diseases, including ACS, burn injury and sepsis [2]. In particular, clinical severity is the major determinant of elevated TPO levels in patients with sepsis [3]. AP is a relatively common disease whose diagnosis and treatment are often dif cult, especially in the clinical setting of the emergency department (ED). About 20% of patients with AP develop a severe form of the disease. In order to early identify those patients af ected by severe A P, several biomarkers have been studied. No data regarding TPO plasma levels in patients with AP are currently available. Methods We enrolled patients with AP at the moment of the first clinical evaluation in the ED. AP patients were classif ed as having mild or severe forms of AP on the basis of the APACHE II score (?8). TPO concentrations were determined by ELISA. (Graph Presented) Results We studied 41 patients with AP (17 severe and 24 mild pancreatitis). No differences for gender and age were detected between patients with mild and severe disease. TPO plasma levels were significantly higher in patients with severe AP (99.33 ± 23.68 pg/ml) than in those with mild AP (50.81 ± 6.73 pg/ml) (Figure 1). The ROC curve led us to calculate a cutof value of 51.55 pg/ml. This value identif ed correctly 12 out of the 17 patients af ected by severe A P. Conclusion TPO may be proposed as biomarker of clinical severity in patients with AP at the time of first evaluation in the ED. Further studies, involving larger numbers of patients, are needed in order to validate these prelimin

DOI : 10.1186/cc12346

Keywords

thrombopoietin; biological marker; growth factor; patient; human; acute pancreatitis; intensive care; emergency medicine; blood level; sepsis; burn; diseases; leukocyte activation; neutrophil; thrombocyte aggregation; megakaryocyte; receiver operating characteristic; pancreatitis; clinical evaluation; emergency ward; gender; diagnosis; enzyme linked immunosorbent assay; APACHE;